Mesalazine granules promote disease clearance in patients with mild‐to‐moderate ulcerative colitis

Abstract

AbstractBackgroundOver the past decade, treatment targets for ulcerative colitis (UC) have become more stringent, incorporating multiple parameters. Recently, the concept of ‘disease clearance’—defined as combined clinical, endoscopic, and histological remission—has been proposed as an ultimate endpoint in treating UC.ObjectiveTo determine the rates of disease clearance in patients with mild‐to‐moderate UC treated with different doses of mesalazine granules as induction therapy.MethodsIn a post hoc analysis, data were pooled from four randomised, active‐controlled, phase 3 clinical trials in patients with mild‐to‐moderate UC receiving 8‐week induction therapy with mesalazine granules at daily doses of 1.5, 3.0 or 4.5 g. Rates of clinical, endoscopic, and histological remission were determined using stringent criteria and used to calculate rates of the composite endpoints of clinical plus endoscopic remission, endoscopic plus histological remission, and disease clearance (clinical plus endoscopic plus histological remission).ResultsA total of 860 patients were included in the analysis. Among the total population, 20.0% achieved disease clearance with mesalazine granules: 13.1% in patients receiving 1.5 g mesalazine granules/day, 21.8% in those receiving 3.0 g/day and 18.9% in those receiving 4.5 g/day. Among patients with moderate UC, 16.8% achieved disease clearance: 7.1% with 1.5 g/day, 18.8% with 3.0 g/day and 16.2% with 4.5 g/day.ConclusionDisease clearance, proposed to be predictive of improved long‐term outcomes, can be achieved in a clinically meaningful proportion of mild‐to‐moderate UC patients treated with mesalazine granules. A daily dose of 3.0 g appears optimal to reach this target.